GDF10 Calms Scar-Forming Liver Cells and Reverses Fibrosis in Mice
A little-studied TGF-β family protein, GDF10, blocks fibrotic signaling in hepatic stellate cells and reversed liver fibrosis in mouse MASH models, including via mRNA nanoparticles.
Summary
Liver fibrosis determines outcomes in MASH, yet no approved drugs target it directly. This preclinical study examined GDF10, a TGF-β superfamily member found mainly in hepatic stellate cells (HSCs), the cells that produce scar tissue. Its expression fell as fibrosis worsened in mouse models and human cirrhotic livers. Boosting Gdf10 with AAV vectors in diet-induced MASH and CCl4 fibrosis models reduced collagen deposition, liver enzymes (ALT/AST), and fibrogenic genes without changing glucose or lipid metabolism. Mechanistically, GDF10 competes with TGF-β1 for the TGF-β receptor 2, limiting SMAD2/3 activation and pushing activated HSCs toward a quiescent, less glycolytic state. The team also built liver-targeted lipid nanoparticles carrying Gdf10 mRNA that reached HSCs and reversed fibrosis in multiple animal models. Findings are preclinical and require human validation.
Detailed Summary
Liver fibrosis is the strongest predictor of liver-related death in metabolic dysfunction-associated steatohepatitis (MASH), a condition affecting a large share of adults worldwide. Despite this, there are no approved therapies aimed specifically at fibrosis. Hepatic stellate cells (HSCs) drive scarring when activated by TGF-β, but the natural factors that return these cells to a quiescent state are poorly understood.
The researchers focused on growth differentiation factor 10 (GDF10), a lesser-known TGF-β family member. Single-cell RNA sequencing showed that Gdf10 in the liver is expressed specifically in HSCs, and that its levels fall as HSCs become fibrotic. They tested gain and loss of function in mice with diet-induced MASH (high-fat/fructose/cholesterol and high-fat methionine/choline-deficient diets) and carbon tetrachloride (CCl4)-induced fibrosis. They used AAV-mediated overexpression, lentiviral knockdown, recombinant GDF10 protein, and cultured primary and immortalized HSCs. Mechanistic work included immunoprecipitation, SMAD2 nuclear translocation assays, Seahorse metabolic flux analysis, and RNA-seq. Finally, they formulated lipid nanoparticles (LNPs) carrying Gdf10 mRNA and tested them in vitro and in fibrosis models.
Gdf10 overexpression reduced collagen deposition, serum ALT/AST, and fibrogenic gene expression in both MASH and CCl4 models, without altering glucose tolerance, insulin sensitivity, or lipid measures. In HSCs, GDF10 competitively bound TGF-β receptor 2, disrupting TGF-β1 engagement, reducing SMAD2/3 phosphorylation and nuclear translocation, and suppressing extracellular matrix production. It also reversed the hypermetabolic, glycolytic profile of activated HSCs, shifting them toward a quiescent-like state. Liver-targeted Gdf10 mRNA LNPs delivered to HSCs and reversed fibrosis in several animal models. In human cirrhotic liver samples, GDF10 expression was reported to correlate with fibrosis severity.
These results position GDF10 as a dual regulator of TGF-β signaling and HSC metabolism, and the mRNA-LNP approach as a possible translatable platform for antifibrotic therapy that avoids systemic metabolic effects. Because TGF-β inhibition has historically been hard to do safely, a naturally occurring, cell-restricted brake on the pathway is attractive.
Caveats: all efficacy data come from mice and cultured cells, with relatively short interventions and model-specific fibrosis. Recombinant and mRNA dosing, durability, immunogenicity, off-target delivery, and effects on cancer risk remain untested. The human data are correlative, and the exact direction of GDF10 expression in human disease needs confirmation in larger cohorts.
Key Findings
- Gdf10 is expressed specifically in hepatic stellate cells, and its levels fall as fibrotic activation increases.
- AAV-driven Gdf10 overexpression cut collagen deposition, ALT/AST, and fibrogenic genes in diet-induced MASH and CCl4 fibrosis models.
- GDF10 competitively binds TGF-β receptor 2, blunting SMAD2/3 phosphorylation, nuclear translocation, and matrix production.
- GDF10 reversed the glycolytic, hypermetabolic state of activated HSCs, restoring a quiescent-like phenotype.
- Liver-targeted Gdf10 mRNA lipid nanoparticles reached HSCs and reversed fibrosis in multiple animal models without altering glucose or lipid metabolism.
Methodology
Preclinical study combining single-cell RNA sequencing, mouse models (HFFC and HFMCD diets, CCl4), AAV8 overexpression, lentiviral knockdown, and recombinant protein dosing. Mechanisms were tested in primary and immortalized HSCs and LX2 cells using immunoprecipitation, nuclear translocation assays, Seahorse metabolic analysis, and RNA-seq, followed by mRNA-LNP testing and human cirrhotic liver analysis.
Study Limitations
Evidence is largely from mouse models and cell culture, with short treatment durations and no long-term safety, toxicity, or immunogenicity data for GDF10 or the LNPs. Human data are correlative and limited, and effects on hepatocellular carcinoma risk and other tissues expressing TGF-β receptors were not established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: